Article
Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: German Health Technology Assessment-Driven Analyses From the BEACON CRC Study.
Clinical colorectal cancer - 1 Sept 2022
Stintzing Sebastian, Seufferlein Thomas, Rosé Christian, Reichenbach Frank, Lüftner Diana
Abstract excerpt
BACKGROUND: Purpose of this analysis was to report data of the BEACON CRC trial used in the German Health Technology Assessment (HTA) and previously unpublished data focusing on the dual blockade (encorafenib + cetuximab) and appropriate comparative therapy (ACT/control: cetuximab + irinotecan-based chemotherapy) of patients with BRAFV600E-mutant mCRC. MATERIALS AND METHODS: Analyses included overall survival...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.